![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 6 of 6. This is the beginning of the thread.
Posted by ihatedrugs on October 5, 2010, at 15:37:00
As it seems, we better get used to the crappy drugs we have now as it is not going to get any better for a while.
Posted by SLS on October 5, 2010, at 16:04:51
In reply to Just the new we've been hoping to hear!, posted by ihatedrugs on October 5, 2010, at 15:37:00
> As it seems, we better get used to the crappy drugs we have now as it is not going to get any better for a while.
>
>
>
> http://www.medscape.com/viewarticle/721671Novartis purchased the rights to develop agomelatine (Valdoxan) in the US. I just hope that it doesn't turn out that Novartis, in effect, actually prevents the development of this drug by shelving CNS drug discovery projects. It could happen. Agomelatine seems to be novel in that it stimulates melatonin M1 and M2 receptors while selectively antagonizing serotonin 5-HT2c receptors. Clinical studies submitted to the EU have demonstrated efficacy. The drug has not yet been embraced by psychiatry in Europe. I don't know why.
- Scott
Posted by ed_uk2010 on October 5, 2010, at 16:13:50
In reply to Re: Just the new we've been hoping to hear! » ihatedrugs, posted by SLS on October 5, 2010, at 16:04:51
>The drug has not yet been embraced by psychiatry in Europe. I don't know why.
It's not well known. Those that do know about it seem to consider it expensive but unreliable.
Posted by Phillipa on October 5, 2010, at 19:09:47
In reply to Re: Just the new we've been hoping to hear! » SLS, posted by ed_uk2010 on October 5, 2010, at 16:13:50
That is also what I read kind of weak? Phillipa
Posted by europerep on October 6, 2010, at 11:22:44
In reply to Re: Just the new we've been hoping to hear! » ihatedrugs, posted by SLS on October 5, 2010, at 16:04:51
>Clinical studies submitted to the EU have demonstrated efficacy. The drug has not yet been embraced by psychiatry in Europe. I don't know why.
>
because it appears to not be that great after all. some of the studies didn't show significant difference from placebo, although in one of them, the parallel drug fluoxetine didn't distinguish itself from placebo either. my doc said he prescribed in several times, in cases for which it was indicated (circadian rhythm thing etc..) and so far, none of the patients stayed on it.. plus it is indeed expensive. but, I agree, it should be given more time.. maybe it only works for a small amount of people, but in them it works great..also, in the latest study I know, 25mg differed from placebo at week 8, whereas 50mg did not.. very strange..
Posted by bleauberry on October 8, 2010, at 16:46:51
In reply to Just the new we've been hoping to hear!, posted by ihatedrugs on October 5, 2010, at 15:37:00
In the meantime, why would someone NOT explore what else to do besides wait for some neurotransmitter manipulator?
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.